'GLP-1 Brides' have a new problem to weigh
Brides-to-be have one more thing to worry about: they’re losing so much weight on GLP-1 drugs that the dresses they ordered no longer fit them. And some are even resorting to plastic surgery
Brides-to-be have one more thing to worry about: they’re losing so much weight on GLP-1 drugs that the dresses they ordered no longer fit them. And some are even resorting to plastic surgery
A new collaboration will work on the development of a treatment involving gene therapy for a condition that affects 10-20 per cent of middle-aged Australians
Redundancies, restructures and tighter headcounts have triggered a shift away from traditional linear career progression with most new jobs in industry now a "sideways move" rather than a promotion
Senior leader named as Director of Policy and External Engagement just as the industry body heads into crucial Strategic Agreement negotiations
Company confirms it has decided to discontinue a long-standing cancer drug from the Australian market on the same day as its anaemia therapy due to an evolving treatment landscape
Doctors have lifted the lid on what they really want when it comes to medical information, with non-pharma companies ready to disrupt industry's relationship with HCPs
A survey of specialists including Aussie clinicians reveals that where treatments look clinically similar, the emotional connection a brand builds separates it from the rest
On the 7.30 Report this week Dave Ricks made it clear he was not interested in accepting a low-ball price to have the company's blockbuster drug listed on the PBS
A researcher has won the AAMRI RIsing Star Award, sponsored by CSL, for her groundbreaking research into gut immunity and inflammatory disease
This company has been ordered to face trial over allegations it defrauded investors by withholding information about a clinical trial for a next-gen drug
With 10 prescription medicine applications on the TGA's review list, this pharma is at the forefront of bringing new therapies to Australia
On a sabbatical year, this well-known industry executive has entered the Australian Portrait Artist of the Year Competition, painting Dannii Minogue
A rapid review will be held into MS drugs to see whether PBAC processes compare them appropriately when recommending cost-minimised listings
Who's nabbed the former Health Minister as a Non-Executive Director to advise on medicines policy and support the company's next phase of growth?
With this company ready to accelerate growth, a successful entrepreneur known across industry takes on Chair role after an oversubscribed seed funding round
The Aussie giant said it stands behind the science of the new technology but changes to the regulatory regime in the US has made the broader market less attractive